Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | FPR1 | P21462 | 2/20 | 0.30 |
| ▸ | FPR2 | P25090 | 2/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987989 | 0.80 | F10 (0.32) | F10 | |
| SCHEMBL28703156 | 0.79 | F10 (0.42) | FPR1FPR2F10 | |
| SCHEMBL27613671 | 0.78 | FPR1 (0.39) | SLC6A9FPR1FPR2F10 | |
| SCHEMBL6987993 | 0.78 | F10 (0.45) | F10 | |
| SCHEMBL4683472 | 0.76 | F10 (0.52) | FPR1FPR2F10 | |
| SCHEMBL6989708 | 0.73 | F10 (0.42) | FPR1FPR2F10 | |
| SCHEMBL27613708 | 0.71 | FPR1 (0.39) | SLC6A9FPR1FPR2F10 | |
| SCHEMBL27613709 | 0.69 | FPR1 (0.47) | FPR1FPR2 | |
| SCHEMBL28704466 | 0.69 | F10 (0.43) | SLC6A9FPR1FPR2F10 | |
| SCHEMBL7411266 | 0.69 | PTGS2 (0.43) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |